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and medical environment for patient suffering from 
psoriasis.
PSN18
PSORIASIS: QUALITY OF LIFE ACCORDING TO
GENDER
Taïeb C, Marionneau N, Myon E
Pharmaco Economics & Quality of Life Department,
Boulogne Billancourt, France
Psoriasis has a heavy impact on the physical and mental
well-being of the patient, especially when the areas
affected are visible to others. Do women affected by pso-
riasis suffer more than men in this respect? OBJECTIVE:
To evaluate the quality of life level of patients with 
psoriasis according to gender. METHOD: Within the
context of the SPOT study, 542 patients (298 men/244
women) responded to a qol questionnaire consisting of a
generic scale (SF-12) and a speciﬁc scale (PDI–Psoriasis
Disability Index). The completed questionnaires were
returned in prepaid envelopes. RESULTS: The socio-
demographic proﬁle of the patients in the two groups did
not present any statistically signiﬁcant difference The
mean age was respectively 46.3 years for the men versus
44.6 years for the women. The PDI score was 11.9% (SD
= 11.7) for the men and 14.8% (SD = 14.4) for the
women; the difference was statistically signiﬁcant (p =
0.031). For the Work, Social relations, Leisure and Treat-
ment dimensions, no difference was observed between the
two sexes: respectively 6.8% (SD = 13.6), 13.0% (SD =
19.4), 12.5% (SD = 16.5), 11.6% (SD = 18.2) in men
versus 7.9% (SD = 15.2), 14.7% (SD = 23.1), 14.1% 
(SD = 18.2), 11.8% (SD = 20.6) in women. On the other
hand, for the Daily Activities dimension the score was
14.0% (SD = 13.3) for the men and 19.9% (SD = 18.4)
for the women. The difference was statistically signiﬁcant
(p < 0.0007). With regard to the SF-12, the results were
organised in 2 scores: mental (MCS-12) and physical
(PCS-12). The scores for the men were: PCS-12 = 51.3
(SD = 7.6) & MCS-12 = 43.4 (SD = 10.0). The scores 
for the women were: PCS-12 = 51.6 (SD = 7.9) & 
MCS-12 = 40.1 (SD = 11.3). With regard to the mental
dimension, the difference was statistically signiﬁcant 
(p < 0.0005). CONCLUSION: Psoriasis modiﬁes the
quality of life more greatly for women, who suffer more
than men. This is especially true for the mental dimen-
sion (SF12) and for the daily activities dimension as
shown by the PDI.
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Dehen L1, Dubertret L1,Aube I2, Myon E3,Taïeb C3
1Hôpital St Louis, Boulogne Billancourt, France; 2Pierre Fabre
Dermatologie, Boulogne Billancourt, France; 3Pharmaco
Economics & Quality of Life Department, Boulogne
Billancourt, France
By deﬁnition, dermatological pathologies have an effect
on one’s self-image, and this may lead to severe psycho-
logical troubles. OBJECTIVES: To evaluate depressive
symptomatology–DS-in patients suffering from chronic
dermatosis. To evaluate the effect of chronic dermatosis
on depressive symptomatology in France for patients
going to a medical consultation at Saint Louis Hospital
(Paris—France). METHODS: The CES-D was remitted to
every patients entering any dermatological consulting
room at Saint Louis Hospital. Two groups were identi-
ﬁed: population coming to a speciﬁc and thematic
doctor’s visit (psoriasis, atopic dermatitis, . . .)—usual
visits or patients coming to the “consultation porte”
(doctor visits without any appointment and taking care
of more distressed dermatological diseases). RESULTS:
The “consultation porte” represents around 22% of the
doctor’s visits versus 78% for the usual visits visits. In 
the studied population (n = 774), 23.6% of the patients
reported depressive symptomatology (CES-D+) whereas
76.4% did not (CES-D-). For patients coming to the
“consultation porte” CES-D+ population represents
31.4% (n = 172) vs 21.4% in the patients having usual
visit (n = 602). As shown, depressive symptomatology is
more often reported for patient coming to the “consulta-
tion porte” compared to patients coming to the usual
visits. This difference is statistically signiﬁcant (test Chi 2
p < 0.01). If we compare the depressive symptomatology
incidence according to dermatological disease, the results
are the following: psoriasis 19%, atopic Dermatitis 28%,
acne 32, and nævi 13%. CONCLUSION: These results
thus give us an idea of both the extent and the impor-
tance of the psychological impact that dermatological 
diseases usually generate. Global disease management
together with psychological support therefore seems
essential for patients suffering from chronic dermatosis.
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OBJECTIVES: To assess the impact of psoriasis vulgaris
treatment with tacalcitol on quality of life. METHODS:
An epidemiological, observational, prospective and mul-
ticenter study of a cohort of patients with mild to mod-
erate Psoriasis vulgaris has been performed. Patients have
been treated with tacalcitol ointment (4mg/g). Anthro-
pometric and demographic characteristics of patients
were recorded in addition to percentage of affected area
and previous and current treatments. Symptomatology
(erythema, desquamation and thickness) was evaluated
by a scale from 0 (absent) to 4 (maximum intensity of
symptom). At follow-up (15 and 60 days) symptomatol-
ogy and appearance of adverse effects were registered.
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Psoriasis Area Severity Index (PASI) was calculated at
each time. Health related quality of life forms SF-12 and
Psoriasis Disability Index (PDI) were completed at the
inclusion and ﬁnal visits. RESULTS: Seven hundred
thirty-one patients out of 1286 were included to perform
quality of life analysis. (54.67% men and 45.33%
women). Mean age was 43.59 ± 15.48 years and BMI
25.07 ± 3.84. Mean affected area at inclusion was
15.97% ± 8.14. Basal PDI was 29.20 ± 14.30. Bigger
values for PDI, and therefore worse quality of life, were
registered in patients with PASI values between 10–50
(28.06 ± 15.26) vs. those whose PASI values were below
10 (34.18 ± 13.60 p < 0.001). After 2 months of treat-
ment, most of patients improved their quality life index:
85.20% for PDI, 51.78% for SF-12 physical domains and
83.30% for SF-12 psychical domains. CONCLUSIONS:
Tacalcitol treatment has a positive effect on health related
well-being, improving quality of life measured by unspe-
ciﬁc scales and also by dermatologic indexes such as PDI.
Tacalcitol treatment increases SF-12 scores, especially
those for psychical domains, resulting in improvement on
patients self-esteem.
METHODOLOGICAL ISSUES
METHODOLOGICAL ISSUES—Compliance
Studies
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PROPERLY ADDRESSING TIME-DEPENDENCE
WHEN ANALYZING THE IMPACT OF
COMPLIANCE WITH MEDICATION IN CHRONIC
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OBJECTIVES: A common problem in outcomes research
is translation of enhanced tolerability or convenience to
higher compliance and better effectiveness. This is par-
ticularly tricky for chronic illnesses where time-dependent
factors act in tandem. The objective was to develop an
approach to this problem for administrative database
analyses. METHODS: Data on women with osteoporo-
sis who received medication (1996–2001) were obtained
from Saskatchewan Health. Using dispensing records,
each subject’s compliance pattern was derived; hospital-
ization/physician service records were used to determine
fracture occurrence. Patients were highly compliant if dis-
pensings covered a minimum portion (e.g., 80%) of their
follow-up time. RESULTS: The common approach is to
compare event rates among compliance categories, using
Cox regression to adjust for confounders and relaxing the
assumption of constant rates. Our rates were 8.3% and
11.1% for high and low compliance, respectively (RR =
0.75); the effect estimated from a Cox regression was RR
= 1.24, and RR = 1.29 when adjusted for confounders,
suggesting a detrimental effect for increased compliance.
This analysis is inherently biased, however, since the
timing of compliance measurements in the risk sets of the
Cox model are not concurrent; the compliance of the sur-
vivors in the risk set is deﬁned over a longer period and
so is prone to be lower than the compliance of the subject
who suffered the fracture. Thus, poor compliance
becomes correlated with longer survival and produces
contradictory ﬁndings. This can be resolved by measur-
ing compliance based on medication use only up to the
time of the fracture for all members of a given risk set.
This analysis produced a crude RR = 0.81, and 0.84 when
controlling for other risk factors. CONCLUSIONS: It is
feasible to obtain population-based estimates of the
impact of compliance on outcomes using an administra-
tive database, but the analysis techniques should properly
account for the time dependencies of all pertinent 
variables.
METHODOLOGICAL ISSUES—Clinical Outcomes
Studies
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DISABILITY IN STROKE OUTCOMES
RESEARCH: CLINICAL MEANING OF THE
BARTHEL INDEX,THE FUNCTIONAL
INDEPENDENCE MEASURE AND THE MODIFIED
RANKIN SCALE
Kwon S1, Hartzema AG1, Duncan PW1, Lai SM2
1University of Florida, Gainesville, FL, USA; 2University of
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OBJECTIVES: Residual disability after stroke presents a
major economic and humanistic burden. To quantify dis-
ability in patient, three disability instruments are globally
used: the Barthel Index (BI), Motor component of Func-
tional Independence Measure (M-FIM), and Modiﬁed
Rankin Scale (MRS). Study objectives are: 1) to develop
a crosswalk among these measures by categorizing scores
presenting clinical signiﬁcance; and 2) to examine the
variation of the categorization scheme over time from
stroke onset. METHODS: The Kansas City Stroke Study
(KCSS) data was utilized for the current study. Disability
measures at baseline (stroke index date), one, three and
six month after index date were collected by trained clin-
icians. Polytomous logistic regression analysis was
applied to produce probabilistic distributions of BI or M-
FIM scores, representing clinically distinct disability
states, which were deﬁned by the six levels of the MRS.
Model ﬁt statistics were examined to verify logistic model
appropriateness. A categorization scheme, which mini-
mized the false positive response rate, was selected as the
optimal categorizing system. RESULTS: BI and M-FIM
differentiated disability well in lower ADLs than higher
ADLs. For BI, 4 clinically distinct disability levels were
differentiated with the following categorization scheme:
0 £ MRS5 < 15, 15 £ MRS4 < 70, 70 £ MRS3 < 95, and
95 £ MRS(0 + 1 + 2) £100. For the M-FIM, 3 stages were
